OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share news the company is reporting the first patient has been dosed in the Phase 2 trial of OK-101, a topical ocular treatment for neuropathic corneal pain (NCP). This double-masked, randomized, 12-week placebo-controlled trial will enroll 48 patients, all of whom will have their NCP disease confirmed via confocal microscopy. The trial is being conducted at a single center under the leadership of Dr. Pedram Hamrah from Tufts Medical Center, where he serves as Professor and Vice Chair of Research and Academic Programs, and Director of the Center for Translational Ocular Immunology. Dr. Hamrah’s expertise will guide the study, which aims to evaluate the effectiveness of OK-101 in alleviating pain caused by corneal nerve damage—a condition with no current FDA-approved treatments. Jacob highlighted that OK-101 is a novel, non-opioid therapeutic specifically designed to target the severe and often debilitating pain associated with NCP. This condition can stem from various sources, including dry eye disease, surgery, or infections, and can significantly affect patients' quality of life. Presently, treatment options for NCP are limited to temporary pain relief strategies that often fall short of providing long-term relief. OKYO Pharma’s development of OK-101 is a promising step toward addressing this unmet medical need, potentially offering patients a more effective solution to manage their corneal pain. #proactiveinvestors #okyopharmalimited #nasdaq #okyo #NeuropathicPain #OcularPain #OK101Trial #FDAApproval #Biotech #Pharmaceuticals #ClinicalTrial #DrugDevelopment #HealthInnovation#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews